Key clinical point: Daily colchicine treatment cut the rate of cardiovascular disease events following an MI.
Major finding: Daily colchicine treatment cut the rate of cardiovascular disease events by 23%, compared with placebo.
Study details: COLCOT, an international, multicenter, randomized trial with 4,745 patients.
Disclosures: COLCOT received no commercial support. Dr. Tardif has received honoraria from Amarin, DalCor, Sanofi, and Servier; he has an ownership interest in DalCor; and he has received research funding from Amarin, AstraZeneca, DalCor, Esperion, Ionis, RegenxBio, Sanofi, and Servier. Dr. Lloyd-Jones had no disclosures.
Tardif J-C et al. AHA 2019, Abstract.